Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

BACKGROUND: The rising incidence of resistance to currently available antibiotics among pathogens, particularly Gram-negative pathogens, in complicated intra-abdominal infections (cIAIs) has become a challenge for clinicians. Ceftazidime/avibactam (CAZ-AVI) is a fixed-dose antibiotic approved in Eur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kongnakorn, Thitima, Eckmann, Christian, Bassetti, Matteo, Tichy, Eszter, Di Virgilio, Roberto, Baillon-Plot, Nathalie, Charbonneau, Claudie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925481/
https://www.ncbi.nlm.nih.gov/pubmed/31890160
http://dx.doi.org/10.1186/s13756-019-0652-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925481/
https://www.ncbi.nlm.nih.gov/pubmed/31890160
http://dx.doi.org/10.1186/s13756-019-0652-x

Ejemplares similares